S P Hicks Endowed Professor of Pathology
Section Head
Michigan Center for Translational Pathology
Professor of Pathology
Professor of Urology
[email protected]
Available to mentor
Arul M Chinnaiyan
Professor
-
Center MemberMM-PKUHSC Joint Institute
-
Center MemberTaubman Institute
-
Center MemberPrecision Health Initiative
-
Center MemberGlobal REACH
-
Center MemberRogel Cancer Center
-
Center MemberCenter for Computational Medicine and Bioinformatics
-
van Riet J, Saha C, Strepis N, Brouwer RWW, Martens-Uzunova ES, van de Geer WS, Swagemakers SMA, Stubbs A, Halimi Y, Voogd S, Tanmoy AM, Komor MA, Hoogstrate Y, Janssen B, Fijneman RJA, Niknafs YS, Chinnaiyan AM, van IJcken WFJ, van der Spek PJ, Jenster G, Louwen R. Commun Biol, 2022 Apr 8; 5 (1): 338Journal ArticleCRISPRs in the human genome are differentially expressed between malignant and normal adjacent to tumor tissue.
DOI:10.1038/s42003-022-03249-4 PMID: 35396392 -
van Riet J, Saha C, Strepis N, Brouwer RWW, Martens-Uzunova ES, van de Geer WS, Swagemakers SMA, Stubbs A, Halimi Y, Voogd S, Tanmoy AM, Komor MA, Hoogstrate Y, Janssen B, Fijneman RJA, Niknafs YS, Chinnaiyan AM, van IJcken WFJ, van der Spek PJ, Jenster G, Louwen R. Commun Biol, 2022 Apr 8; 5 (1): 338Journal ArticleCRISPRs in the human genome are differentially expressed between malignant and normal adjacent to tumor tissue.
DOI:10.1038/s42003-022-03249-4 PMID: 35396392 -
Dadhania V, Gonzalez D, Yousif M, Cheng J, Morgan TM, Spratt DE, Reichert ZR, Mannan R, Wang X, Chinnaiyan A, Cao X, Dhanasekaran SM, Chinnaiyan AM, Pantanowitz L, Mehra R. BMC Cancer, 2022 May 5; 22 (1): 494Journal ArticleLeveraging artificial intelligence to predict ERG gene fusion status in prostate cancer.
DOI:10.1186/s12885-022-09559-4 PMID: 35513774 -
Dadhania V, Gonzalez D, Yousif M, Cheng J, Morgan TM, Spratt DE, Reichert ZR, Mannan R, Wang X, Chinnaiyan A, Cao X, Dhanasekaran SM, Chinnaiyan AM, Pantanowitz L, Mehra R. BMC Cancer, 2022 May 5; 22 (1): 494Journal ArticleLeveraging artificial intelligence to predict ERG gene fusion status in prostate cancer.
DOI:10.1186/s12885-022-09559-4 PMID: 35513774 -
Eng S, Basasie B, Lam A, Semmes J, Troyer D, Clarke G, Sunnapwar A, Leach R, Johnson-Pais T, Sokoll L, Chan D, Tosoian J, Siddiqui J, Chinnaiyan A, Boutros P, Liss M. Journal of Urology, 2022 May; 207 (Supplement 5): e686Journal ArticlePD40-07 CLINICAL DECISION ALGORITHM USING RESTRICTION SPECTRUM IMAGING AND BIOMARKERS TO PREDICT UPGRADING IN ACTIVE SURVEILLANCE
DOI:10.1097/ju.0000000000002601.07 -
Eng S, Basasie B, Lam A, Semmes J, Troyer D, Clarke G, Sunnapwar A, Leach R, Johnson-Pais T, Sokoll L, Chan D, Tosoian J, Siddiqui J, Chinnaiyan A, Boutros P, Liss M. Journal of Urology, 2022 May; 207 (Supplement 5): e686Journal ArticlePD40-07 CLINICAL DECISION ALGORITHM USING RESTRICTION SPECTRUM IMAGING AND BIOMARKERS TO PREDICT UPGRADING IN ACTIVE SURVEILLANCE
DOI:10.1097/ju.0000000000002601.07 -
Weiner AB, Liu Y, McFarlane M, Bawa PS, Li EV, Zhao X, Li Z, Hammoud T, Hazime M, Karnes RJ, Davicioni E, Reichert ZR, Chinnaiyan AM, Lotan TL, Spratt DE, Schaeffer EM. Prostate Cancer Prostatic Dis, 2022 Apr; 25 (4): 659 - 665.Journal ArticleA transcriptomic model for homologous recombination deficiency in prostate cancer.
DOI:10.1038/s41391-021-00416-2 PMID: 34226663 -
Labanca E, Yang J, Shepherd PDA, Wan X, Starbuck MW, Guerra LD, Anselmino N, Bizzotto JA, Dong J, Chinnaiyan AM, Ravoori MK, Kundra V, Broom BM, Corn PG, Troncoso P, Gueron G, Logothethis CJ, Navone NM. Eur Urol Oncol, 2022 Apr; 5 (2): 164 - 175.Journal ArticleFibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer.
DOI:10.1016/j.euo.2021.10.001 PMID: 34774481
Health Lab
In two separate papers, U-M researchers describe how a gene alteration drives prostate cancer and a potential degrader that stops it
Health Lab
Researchers have uncovered a key reason why a typically normal protein goes awry and fuels cancer. They found the protein NSD2 alters the function of the androgen receptor, an important regulator of normal prostate development.
Health Lab
A study from the University of Michigan Health Rogel Cancer Center furthers research that suggests the potential of developing new cancer treatments to target oncogenic transcription factors by indirectly affecting their ability to access enhancer DNA in chromatin.